Eikon Therapeutics Inc Dossier - Source-backed chat

Eikon Therapeutics Inc

EIKNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.41Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $401.4M

Shares Outstanding 54.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Eikon Therapeutics is a newly public, late-stage clinical biopharmaceutical company led by a highly experienced management team of former Merck executives. The company's investment case is highly speculative, centered on its lead asset EIK1001 (a TLR7/8 dual agonist) in combination with Keytruda (pembrolizumab) for NSCLC and melanoma, alongside its selective PARP1 inhibitor EIK1003. While early Phase 2 data is encouraging, pivotal registrational readouts are not expected until 2027. Furthermore, the company faces near-term headwinds including a limited cash runway extending only into the second half of 2027, potential equity dilution, and the expiration of the insider lock-up period in August 2026. A Hold rating is recommended to observe clinical progress and wait out near-term technical selling pressure.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$24.80

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The bear case materializes if EIK1001 combination trials fail to show a statistically significant survival benefit over standard of care, or if safety concerns (such as severe cytokine release syndrome or systemic toxicities) limit its therapeutic window. Additionally, EIK1003 fails to differentiate itself from competing selective PARP1 inhibitors in development. Rapid cash burn forces a highly dilutive down-round equity raise under unfavorable market conditions, and the stock experiences severe downward pressure following the August 2026 lock-up expiry.

Base CaseCentral scenario

$24.8050%

Matches the consensus mean

The base case assumes EIK1001 continues to show steady clinical progress with acceptable safety profiles, but major registrational readouts are delayed or require extended follow-ups into late 2027. EIK1003 advances through Phase 1/2 trials, confirming its PARP1 selectivity. The company is forced to raise additional capital in early 2027, causing moderate shareholder dilution. The stock trades in a range-bound manner, heavily influenced by broader biotech market sentiment and technical pressure from the August 2026 lock-up expiration.

Bull CaseUpside scenario

$32.0030%

The bull case is driven by positive registrational data from the EIK1001 combination trials in melanoma and NSCLC, proving that TLR7/8 dual agonism significantly enhances the efficacy of checkpoint inhibitors. Additionally, EIK1003 demonstrates superior safety with minimal hematological toxicity compared to first-generation PARP inhibitors, allowing for broad combination therapies and early-line use. Eikon's proprietary single-molecule tracking platform successfully validates its AI-driven drug discovery capabilities, attracting lucrative biopharma partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Led by a world-class management team, including CEO Roger Perlmutter and CMO Roy Baynes, who previously directed the development and global expansion of Keytruda at Merck.
Encouraging early clinical data for lead asset EIK1001, showing a 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR) in combination with pembrolizumab and chemotherapy in first-line NSCLC.
EIK1003 is a highly selective PARP1 inhibitor designed to spare PARP2, potentially reducing hematological toxicities and enabling broader combination regimens.
Proprietary single-molecule tracking (SMT) platform and machine learning capabilities provide long-term discovery optionality.

Key Investment Risks

High cash burn rate with a cash runway extending only into the second half of 2027, indicating a high probability of dilutive equity financing within the next 12 months.
Pivotal registrational trial readouts for the lead programs are not expected until 2027, leaving a lack of major clinical catalysts in the near term.
Technical selling pressure and stock volatility risks associated with the expiration of the insider lock-up period in August 2026.
Heavy reliance on in-licensed clinical assets rather than internally discovered platform candidates to drive near-to-mid-term value.

Thesis Invalidation Triggers

Failure of EIK1001 to meet primary endpoints in the Phase 2/3 registrational trials for advanced melanoma or stage 4 NSCLC.
Severe safety signals, such as high-grade cytokine release syndrome (CRS) or unexpected systemic toxicities, that halt clinical development of EIK1001.
Inability to secure additional financing on reasonable terms, leading to severe capital constraints or extreme dilution.
EIK1003 failing to demonstrate a superior hematological safety profile compared to first-generation PARP inhibitors in clinical trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.